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Background: Complicated skin and skin-structure infections (cSSSI), including surgical site infections
(SSI), cellulitis, and abscesses, have been extensively studied, but controversial issues still exist.
Controversial issues: The aim of this GISIG (Gruppo Italiano di Studio sulle Infezioni Gravi) working group
– a panel of multidisciplinary experts – was to deﬁne recommendations for the following controversial
issues: (1)What is the efﬁcacy of topical negative pressure wound treatment as compared to standard of
care in the treatment of severe surgical site infections, i.e., deep infections, caused by Gram-positive
microorganisms? (2) Which are the most effective antibiotic therapies in the treatment of cSSSI,
including SSI, due to methicillin-resistant staphylococci? Results are presented and discussed.
Methods: A systematic literature search using the MEDLINE, EMBASE, Cochrane Central Register of
Controlled Trials, and www.clinicaltrials.gov databases of randomized controlled trials and/or non-
randomized studies was performed. Amatrix was created to extract evidence from original studies using
the CONSORT method to evaluate randomized clinical trials and the Newcastle–Ottawa Quality
Assessment Scale for case–control studies, longitudinal cohorts, and retrospective studies. The GRADE
methodwas used for grading quality of evidence. An analysis of the studies published between 1990 and
2008 is presented and discussed in detail.
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Complicated skin and skin-structure infections (cSSSI), includ-
ing surgical site infections, cellulites, and abscesses, are common
infections, generally caused by Gram-positive cocci, with Staphy-
lococcus aureus and streptococci being the most common etiologic
agents. Inmany countries throughout theworld, these infections in
the hospital setting are due in a worryingly increasing proportion
to antibiotic-resistant strains, such as methicillin-resistant S.
aureus (MRSA).1 Over the last few years, community-acquired
MRSA (CA-MRSA) has become a common problem in North
America,2 while CA-MRSA of pig or cattle origin, also known as
livestock-associated MRSA (LA-MRSA), has been identiﬁed inses. Published by Elsevier Ltd. All rights reserved.
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These epidemiological changes are important and should hamper a
revisionof the literature regardingdifferent aspects of the treatment
of cSSSI, with a special interest in surgical site infection (SSI).
Different aspects have emerged as interesting in the ﬁeld of cSSSI,
particularly of those caused by MRSA: prevention and antibiotic
therapy, as well as non-antibiotic therapy of SSI.
First, the availability of rapid identiﬁcation systems for S.
aureus, mostly based upon molecular techniques, now permit the
identiﬁcation of subjects colonized by these germs in a few hours,
either methicillin-resistant (MRSA) or methicillin-sensitive
(MSSA). The early identiﬁcation and treatment of these subjects
can be both clinically and epidemiologically useful, with the aim of
reducing infections in colonized subjects, tailoring antibiotic
prophylaxis, and limiting the nosocomial spread of the bacterium.
Second, cSSSI have represented a common setting for the
registration of many new antibiotics, including linezolid,6,7
tigecycline,8 ceftobiprole,9 and daptomycin.10 Most recent com-
parative studies have evaluated the non-inferiority of a newer drug
compared with the standard of care, i.e., a glycopeptide, with costs
of the newer drugs being generally much higher than the older
ones. A global revision of the results, taking into account the
quality of the different studies, to better deﬁne the best clinical
setting for newer drugs, is needed.
Third, treatment of infected post-surgical wounds may be based
upon different strategies, including surgery, antibiotics, dressings,
and topical negative pressure (TNP) therapy, deﬁned also as vacuum
associated closure (VAC).5,11–16 TNP/VAC is becoming a standard of
care, particularly in the treatment of post-sternotomy infections.17
Although the system may be effective in treating these infections,
the high costs of such an approach and the wide diffusion that TNP/
VAC has reached over recent years, particularly in the treatment of
post-sternotomy infections, including mediastinitis, make this area
of research interesting for a systematic review.
2. Objective
The aim of this studywas to review the literature on the optimal
treatment of cSSSI, including SSI, caused by resistant Gram-
positive strains, with a special focus on studies on newer
antibiotics against Gram-positive resistant microorganisms.
3. Methods
3.1. Controversial issues
Agroupof experts in theﬁeldof cSSSIwas identiﬁedand enrolled
in a faculty. The faculty was in charge of deﬁning controversial
issues, developing a search strategy, and reviewing the retrieved
literature in order to obtain data on controversial issues and to draw
recommendations based on the best available evidence.
During twoworkshopmeetings held inMilan, Italy, the group of
experts, after discussion within the group, and with the board of
the project, identiﬁed the following questions to be addressed:
1. ‘‘Do topical nasalmupirocin or other local treatments reduce the
incidence of surgical site infections?’’ (decolonization). Regard-
ing this question, a meta-analysis was published by the
Cochrane collaboration18 that covered the same target. Since
no relevant paper had been published from May 29, 2008
through February 28, 2009, this analysis was not performed.
2. ‘‘What is the efﬁcacy of topical negative pressure wound
treatment as compared to the standard of care, in the treatment
of severe surgical site infections, i.e., deep, under the fascial
and muscle layers, due to Gram-positive microorganisms?’’
(TNP/VAC).3. ‘‘Which are the most effective therapies in the treatment of
complicated skin and skin-structure infections, including
surgical site infections?’’ (cSSSI).
3.2. Literature search and study selection
To these aims, we systematically reviewed comparative studies
on the above-mentioned controversial issues on cSSSI. Five
different databases were thoroughly searched, namely PubMed,
EMBASE, the Cochrane Central Register of Controlled Trials, UK
Clinical Research Network Study Portfolio and www.clinicaltrials.-
gov. In each database the following search terms were used for the
two questions:
1. TNP: (a) ‘vacuum assisted closure’ OR ‘VAC’ OR ‘topical negative
pressure’ OR ‘TNP’ OR ‘vacuum’ AND (b) ‘wound’ OR ‘chronic
wound’ OR ‘ulcer’ AND (c) ‘infection’.
2. cSSSI: (a) ‘skin infection’ OR ‘soft tissue infection’ OR ‘surgical
wound infection’ OR ‘surgical site infection’ AND (b) ‘Gram-
positive bacteria’ OR ‘Staphylococcus’ OR ‘Staphylococcus aureus’
OR MRSA AND (c) ‘infection’ AND (d) ‘randomized controlled
trial’ (RCT).
A studywas considered eligible for analysis if the criteria listed below
were met. If data were missing for the programmed analysis in the
selected studies, an e-mail requiring data clariﬁcation was sent to the
corresponding author.
3.3. Question 1 – TNP/VAC
1. Population: any person aged 13 years who developed a deep
surgical site infection.Adeepsurgical site infectionwasdeﬁnedas
infection involving the deep soft tissues (e.g., fascial and muscle
layers) of the incision, following the Hospital Infection Control
Practices Advisory Committee 1999 guideline deﬁnition.19
2. Intervention: use of any kind of TNP/VAC to treat the infected
surgical wound.
3. Control: any type of dressing, including traditional wet gauze
dressing and the newer moist dressings, with or without topical
agents.
4. Outcome: infection cure/wound resolution, time to complete
healing, incidence of complications, duration of hospital stay,
incremental costs, quality of life, mortality.
5. Study design: any comparative study either RCT or comparative
non-randomized study (CS), either a case–control or a cohort
comparative study.
3.4. Question 2 - cSSSI
1. Population: patients aged 13 years with a diagnosis of
complicated skin and skin-structure infection.
2. Intervention: intervention drug, i.e., antibiotic with anti-MRSA
activity.
3. Control: comparator, i.e., a second antibiotic or an association of
antibiotics, with anti-MRSA activity.
4. Outcome: clinical cure at the test of cure (TOC) visit, so that no
further antibiotic or surgerywas necessary,microbiological cure
at the TOC visit, incidence of adverse events (AEs), duration of
intravenous therapy, duration of hospital stay, incremental
costs, mortality.
5. Study design: RCT.
The studies were considered eligible if they assessed clinical
and/or microbiological effectiveness, toxicity, or mortality of both
therapeutic regimens. We included both blinded and unblinded
trials as well as any type of statistical design, such as equivalence,
non-inferiority, and superiority studies. Only studies written in
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Figure 1. Flow diagram of trial selection: use of vacuum-assisted closure (VAC) in infected wounds.
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question 2 (cSSSI), RCTs that did not include anyMRSA patientwere
excluded, aswell as those inwhichoneof the study regimensdidnot
have any anti-MRSA activity. Trials focusing on pharmacokinetic or
pharmacodynamic variables were also excluded. RCTs that studied
additional antimicrobial agents, generally with anti-Gram-negative
rods and/or anti-anaerobic activity (as is the case in patients with
polymicrobial infections) were included in the analysis.
3.5. Classiﬁcation and evaluation of the selected evidence
A matrix was made to extract evidence from individual original
studies using the CONSORT method for the evaluation of random-
ized clinical trials and the Newcastle–Ottawa Quality Assessment
Scale for the evaluation of case–control trials, longitudinal cohorts,
and retrospective studies with comparative groups.20 The original
data from case studies were considered homogeneous after using a
predeﬁned format both for single case reports and series of reported
cases.20 In thediscussionsection, toassign thestrength tothe level of
the recommendations, a methodology adapted from the GRADE
Working Group was applied. The details of the methodology are
reported in this supplement.20
3.6. Deﬁnition of infection
3.6.1. Deep surgical site infection
A deep surgical site infection was deﬁned as infection involving
the deep soft tissues (e.g., fascial andmuscle layers) of the incision,
following the Hospital Infection Control Practices Advisory
Committee 1999 guideline deﬁnition.19 Complicated skin and
skin-structure infections (cSSSI) were deﬁned as infectionsinvolving deeper soft tissue and/or requiring signiﬁcant surgical
intervention (e.g., surgical or traumatic wound infection, major
abscess, infected ulcer, or deep and extensive cellulitis) or that had
developed on a lower extremity in a subject with diabetes mellitus
or well-documented peripheral vascular disease. The presence of
at least one local sign of cSSSI (i.e., erythema, ﬂuctuance, purulent
or seropurulent drainage/discharge, heat/localized warmth, pain/
tenderness to palpation, swelling/induration) or one systemic sign
(oral temperature of>38 8C, white blood cell count of>10  109/l,
>10% immature neutrophils) were necessary to deﬁne a cSSSI.
4. Results
4.1. Question 1 – TNP/VAC
‘‘What is the efﬁcacy of the topical negative pressure wound
treatment as compared to the standard of care, in the treatment of
severe surgical site infections, i.e., deep, under the fascial and
muscle layers, due to Gram-positive micro-organisms?’’
A total of 10 comparative studies were identiﬁed (see Figure 1).
Of these, six were on post-sternotomy deep surgical site infection,
with or without mediastinitis,21–26 three on post-sternotomy
mediastinitis,27–29 and one on early groin vascular by-pass graft
infection30 (see Tables 1 and 2).
In all studies the main outcome was the cure of the infection or
the failureof the therapy.Although thedeﬁnitionofwoundcurewas
not standardized throughout the studies, the deﬁnition of wound
resolution was based upon the appearance of the wound, the
presence of wound granulation and/or resolution of local signs of
inﬂammation, and/or negative cultures in six studies (see Table 2).
Two studies referred to a deﬁnition of failure, including the need for
Table 1
Data extracted from the comparative studies—I
ID Aim Study design Population Intervention Comparator
Berg 200021 Compare the TNP/VAC and closed
drainage technique
Retrospective comparative
cohort study
Deep surgical site infection of the
sternotomy site with positive cultures
Vacuum suction through 3–6
redon catheters (300–600 mmHg);
no polyester dressing used
2–4 catheters with CDI (2 l of 0.5%
povidone–iodine solution per 24 h
continuously)
Catarino 200027 Compare the TNP/VAC and standard therapy Retrospective comparative
cohort study
Patients with early post-sternotomy
mediastinitis
TNP/VAC 125 mmHg; changed
every 2–3 days
Debridement, CDI with normal saline
(1 l every 6 h until the efﬂuent was
microbiologically clear)
Colwell 200430 Compare debridement/TNP/VAC vs.
incision/drainage+ sartorius or rectus
femoris muscle ﬂaps
Retrospective comparative
cohort study
Patients with early groin vascular
by-pass graft infection
TNP/VAC: not speciﬁed Incision and drainage
Fleck 200422 Compare preconditioning of the wound
with TNP/VAC with conventional
debridement and immediate primary closure
Retrospective comparative
cohort study
Patients with post-sternotomy
wound infection
TNP/VAC 125 mmHg; changed
every 2–3 days
Rewiring and primary
wound closure with insertion of a
mediastinal drain; daily dressing
changes
Fuchs 200523 Compare TNP/VAC with open pack procedure Retrospective comparative
cohort study
Patients with sternotomy and
deep surgical wound infection
TNP/VAC 75–125 mmHg; changed
every 3–7 days
Irrigation with povidone–iodine,
saline and H2O2, with wound
drainage, open packing and
delayed closure
Scholl 200424 Compare TNP/VAC with standard
medication as a method to facilitate
healing (1) as a temporary wound care
technique preoperatively
in patients requiring muscle ﬂap
reconstruction, (2) as the primary method
of wound closure, and (3) in
post-reconstructive wounds complicated
by re-infection
Retrospective comparative
cohort study
Patients with sternotomy and
deep surgical wound infection –
sternal osteomyelitis
TNP/VAC (continuous or
intermittent 25–200 mmHg)+
wound debridement; changed
every 2 days
Debridement; the type of dressing
is not speciﬁed
Segers 200528 Compare TNP/VAC with closed
drainage techniques
Retrospective comparative
cohort study
Post-sternotomy mediastinitis TNP/VAC 75–125 mmHg; changed
after 2 days then every 4–5 days
Debridement followed by closed
drainage technique
Simek 200825 Compare clinical outcomes,
in-hospital mortality and 1-year
survival of topical negative pressure
and conventional therapy
Prospective analysis Deep sternal wound infection TNP/VAC 125 mmHg; changed
every 2–3 days
Debridement followed by chest
rewiring and closed irrigation with
antiseptics for 6–8 days
Sjo¨gren 200529 Compare the failure rate and survival
after single-line TNP/VAC therapy or
conventional treatment
Retrospective comparative
cohort study
Post-sternotomy mediastinitis TNP/VAC 125 mmHg; changed
3/week
Moist saline gauzes changed several
times a day
Song 200326 Compare twice-day gauze with TNP/VAC Retrospective comparative
cohort study
Patients with sternotomy
and sternal wound
TNP/VAC 75–125 mmHg; changed
every 2 days
Twice-day dressing: debridement;
silver sulfadine or mafenide acetate
VAC, vacuum-assisted closure; CDI, continuous drainage irrigation; TNP, topical negative pressure.
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Table 2
Data extracted from the comparative studies—II
ID Outcome 1
Resolution
Outcome 2
Incidence of
complications
Outcome 3
Hospital stay
Outcome 4
Cost per
patient
Outcome 5
Quality
of life
Outcome 6
Mortality
(Time points)
Quality
(risk of
bias)
Notes
Num/Den Num/Den Days
(mean SD)
Num/Den
(I) (C) (I) (C) (I) (C) (I) (C) (I) (C) (I) (C)
Berg
200021
26/31 1,2 14/29 NE NE 4226 5622 NE NE NE NE 2/31 2/29 Medium 1Failure: re-exploration (debridement,
reclosure, a different drainage technique or
(muscle) ﬂap reconstruction) of the sternal
wound within 60 days after the drainage was
applied
(In-hosp)
2Variables signiﬁcantly associated with
treatment failure: S. aureus as causative
pathogen (p=0.04), NYHA score (p=0.04), and
severity of mediastinitis (p=0.02)
S. aureus and severity were worse in CDI
Catarino
200027
9/9 1,2 5/10 NE NE 35 (22–88)* 50 (27–98)* NE NE NE NE 1/9 5/10 Medium 1Resolution: evident granulation tissue and
negative microbiological cultures (speciﬁed
only for TNP/VAC)
(*Median) (FU 6 mo)
2First 2 patients were treatedwith TNP/VAC 26
and 24 days after diagnosis of infection
(initially with CDI)
Colwell
200430
4/4 1 4/5 2 0/4 1/5 NE NE NE NE NE NE 0/4 0/5 Medium 1Resolution: no deﬁnition
(FU 2–24 mo) 2In the comparator arm one was
debridement +packed wet to dry dressings
One reinfection at 4 mo, cured at 2 years
Notably: 10–14 days of antibiotic course
Fleck
200422
35/35 1 62/97 NE NE 19 (7–45)* 24 (5–72)* NE NE NE NE NE 2 NE High 1Resolution of infection: decline of serological
inﬂammation parameters, less than 100 000
CFU per g of tissue in bacteriological
(*Median)
cultures, and resolution of local infection signs
in the wound
2Overall in-hospital mortality: 7%
Fuchs
200523
34/35 1,2 29/33 NE NE 25 (18–35)* 34 (24–55)* NE NE NE NE 1/35 8/33 Medium 1Resolution: 3 negative sternal wound
samples
21 (IQR 15–26)* 28 (18–54)*
(*Median)
2In both study groups, rewiring was done
without the use of muscle ﬂaps or
omentoplasty(*Time to wound healing)
Scholl
200424
6/7 1 6/6 1/7 1/6 NE NE NE NE NE NE 0/7 2 0/6 Medium 1Resolution: no deﬁnition
5 pre-operative, 1 post-op, 1 pre- and post-op
One patient treatedwith TNP/VAC healed after
reoperation
12/13 patients underwent bilateral
pectoralis major muscle ﬂaps for
reconstruction
2Mean FU: 14 mo
Segers
200528
21/29 1 14/34 1/29 0/34 2 46.1 (10–74)* 35.7 (10–167)* NE NE NE NE 1/29 1/34 Medium 1Failure: recurrence of wound infection, a
(*Range) (FU 1 mo) change to other treatment techniques and the
9/29 8/34 need for multiple surgical interventions to
control infection or mortality caused primarily
by the surgical site infection
(FU 12 mo)
2Not clearly speciﬁed
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Table 2 (Continued )
ID Outcome 1
Resolution
Outcome 2
Incidence of
complications
Outcome 3
Hospital stay
Outcome 4
Cost per
patient
Outcome 5
Quality
of life
Outcome 6
Mortality
(Time points)
Quality
(risk of
bias)
Notes
Num/Den Num/Den Days
(mean SD)
Num/Den
(I) (C) (I) (C) (I) (C) (I) (C) (I) (C) (I) (C)
Simek
200825
32/34 1 17/28 6/34 2 4/28 40.216.3 48.829.2 NE NE NE NE 2/34 11/28
11/28
Low 1Resolution of infection: wound bed was
found free of infection, covered by well-
vascularized granulation tissue, and the CRP
level 50mg/L
(In-hosp)
5/34
(FU 12 mo)
Treatment failure: not deﬁned
2Incidence of major bleeding and ﬁstula
Sjo¨gren
200529
61/61 1 25/40 4/61 2 2/40 2517 2520 NE NE NE NE 0/61 6/40 Medium 1Resolution: wound was considered clean and
there was a bed of fresh granulation tissue(FU 3 mo)
All 61 patients in the TNP/VAC group
underwent sternal rewiring without tissue
ﬂap surgery. In the conventional treatment
group, tissue ﬂaps were performed in 57.5%
(23 patients)
Results are stratiﬁed as per type of
mediastinitis (El Oakley class)
2Fistula
Song
200326
14/17 1 17/18 2/14 6/17 NE NE NE NE NE NE 3/17 1/18 Medium 1Resolution: gross appearance of the wound
and hemodynamic stability of the patient
61.3* 82.9*
(In-hosp)
28 mediastinitis, 5 chronic infection and 2
sterile wounds(*Time to
wound
healing)
Number of ﬂaps needed to close the wound:
non-TNP/VAC group=1.50.1,
TNP/VAC group=0.9 0.07 (p<0.05)
Total 242/266 193/300 14/149 14/131 NE NE NE NE 17/132 26/133
NE, not examined; NYHA, New York Heart Association; CDI, continuous drainage irrigation; mo, months; FU, follow-up; IQR, interquartile range; TNP, topical negative pressure; VAC, vacuum-assisted closure; CRP, C-reactive
protein; I, intervention; C, control; Num, numerator; Den, denominator.
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Table 3
Evaluation of the quality of the studies based upon the NOS score
Selection (0–4) Comparability (0–2) Outcome (0–3) Overall quality
Representativeness Selection of
non-exposed
Ascertainment
of exposure
Outcome
of interest
Comparability Control for a
second factor
Assess
outcome
FU long
enough
Adequacy
FU cohorts
Risk of bias
Berg 200021 * * * * * * * 0 0 Medium
Catarino 200027 * * * * * * 0 * 0 Medium
Colwell 200430 * * * * * 0 * 0 0 Medium
Fleck 200422 * * * * 0 0 0 0 0 High
Fuchs 200523 * * * * * * 0 * * Low
Scholl 200424 * * * * * 0 * 0 0 Medium
Segers 200528 * * * * 0 * * 0 * Medium
Simek 200825 * * * * * * 0 * * Low
Sjo¨gren 200529 * * * * * 0 0 * * Medium
Song 200326 * * * * * * 0 0 0 Medium
FU, follow-up; *, item adequately fullﬁlled.
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reported.24,30
4.2. Patient populations
The patient populations were similar between the two study
groups throughout most studies, although in one study no data
regarding the demographic and general characteristics of the two
groups were reported22 and in another overall data only were
available.24 The mean age was similar between the two treatment
groups in all the studies, ranging between 61 and 72.6 years. A
signiﬁcantly higher proportion of females in the TNP/VAC armwas
observed in two studies.28,29 Finally, one study reported a longer
duration of intervention28 and another a higher EUROscore, an
index of surgical complexity,29 and a lower proportion of S. aureus
infections21 in the TNP/VAC arm.
4.3. Intervention
The modalities of TNP/VAC were relatively similar throughout
the studies: a negative pressure of 75–125 mmHg was used in
seven studies, as was the time interval between dressing changes,
i.e. 48–72 h (see Table 1). One study used higher pressures, 300–
600 mmHg,21 another lower pressures (25–200 mmHg).24 In one
study the pressure used was not speciﬁed.30
4.4. Control
The comparative conventional therapies were continuous
drainage irrigation in two studies21,27 and closed drainage
irrigation in ﬁve.22,23,25,28,30
4.5. Study design
Nine studies were retrospective comparative cohort studies,
while a single studywas prospective (see Tables 1 and 2).25 No RCT
was retrieved.Table 4
Grade score of the studies on topical negative pressure (TNP)
Trial Design Quality Inconsistency Directness Attriti
Berg 200021 2 1 0 0 1
Catarino 200027 2 1 0 0 0
Colwell 200430 2 1 0 0 0
Fleck 200422 2 1 0 0 0
Fuchs 200523 2 0 0 0 0
Scholl 200424 2 1 0 0 0
Segers 200528 2 0 0 0 1
Simek 200825 2 0 0 0 0
Sjo¨gren 200529 2 1 0 0 0
Song 200326 2 1 0 0 14.6. Risk of bias of included studies
The comparative studies retrieved generally had a medium risk
of bias, as evaluated through the Newcastle–Ottawa Quality
Assessment Scale (NOS; see Table 3). Only two studies showed a
low risk of bias.23,25 Notably, while bias on the selection of patients
was low in all selected trials, both comparability and outcome
were at higher risk of bias.
4.7. Effects of intervention – primary outcomes
Ten studies were selected for analysis. In none of the studies it
was possible to identify the effect of either treatment on
infections speciﬁcally caused by Gram-positive micro-organ-
isms. The analysis of the results was therefore performed on the
whole group of patients treated with TNP/VAC or conventional
treatment, irrespectively of the etiologic agent. The methodo-
logical quality of these studies was analyzed through the GRADE
system (see Table 4). Of these studies, three enrolled patients
with post-sternotomy mediastinitis, six evaluated patients with
post-sternotomy deep infection, and one study analyzed patients
with early groin vascular by-pass graft infection (see Table 1).
The studies analyzed reported data regarding 562 patients, of
which 262 (47%) had been treated with TNP/VAC and 300 (53%)
with conventional therapy. Concerning the main outcome, i.e.,
cure rate, all studies reported the results as the proportion of
patients cured; two studies also reported the time to wound
healing.23,26
4.8. Results
Six studies reported a difference in wound cure in TNP/VAC as
compared with conventional therapy.21,22,25,26,28 Wound resolu-
tion was obtained more frequently in patients treated with TNP/
VAC (242/262, 92.4%) as compared with patients cured with
standard treatment (193/300, 64.3%) (odds ratio (OR) 6.43, 95%
conﬁdence interval (CI) 3.81–10.85).on Bias Association (RR) Dose/response Confounders Total
1 0 0 0 1
1 +1 0 0 1
1 0 0 0 0
1 0 0 0 0
1 0 0 0 1
1 0 0 0 0
1 0 0 0 0
1 0 0 0 1
1 0 0 0 0
1 0 0 0 1
[(Figure_2)TD$FIG]
Figure 2. Flow diagram of trial selection: antibiotic therapy in complicated skin and skin-structure infections (cSSSI) due to Gram-positive cocci/methicillin-resistant
Staphylococcus aureus (MRSA).
A. Pan et al. / International Journal of Infectious Diseases 14S4 (2010) S39–S53S46Time to wound healing was analyzed in two studies: it was a
median 21 days (interquartile range (IQR) 15–26) in TNP/VAC
treated subjects and 28 (IQR 18–54) in controls (p > 0.05) in one
study, and mean  standard deviation of 6  1.3 in TNP/VAC vs. 8 
2.9.23,26
The incidence of complicationswas reported in 6/10 studies, for
a total of 280 treated patients (see Table 2). None of the studies
reported any difference between TNP/VAC and conventional
therapy regarding the incidence of complications. A complication
was observed in 14/149 (9.4%) patients treated with TNP/VAC and
in 14/131 (10.7%) controls, indicating no signiﬁcant difference
among the groups (OR 0.91, 95% CI 0.42–2.01). Notably, among
complications in patients treated with TNP/VAC, a ventricular
rupture was observed, causing the patient’s death.23
The duration of hospital stay was analyzed in seven studies (see
Table 2). Three studies reported themean values with the standard
deviation,21,25,29 one the mean and the range of values,28 two the
median with the interquartile variation (IQV),23,27 and one the
median with the range.22 Four of these studies reported a
signiﬁcant reduction in hospital-stay in patients treated with
TNP/VAC as compared with conventional treatment.21,23,25,27 In
none of these studies was a conﬁdence interval reported. No cost-
effectiveness analysis or quality of life investigation was
performed in any of the retrieved studies.
Finally, mortality rates were available in 9/10 studies (see Table
2). Three studies reported a reduced mortality rate in patients onTNP/VAC.23,25,26 Different time points were analyzed in the
different studies: two studies presented data regarding in-hospital
mortality,21,26 two studies presented both short-term (either in-
hospital or 1 month) and middle-term (i.e., 1 year) mortality,25,28
and two studies analyzed the 3- and 6-month mortality,
respectively27,29 (see Table 2). In three cases the time-point of
the mortality rate was not clearly speciﬁed. The overall mortality
rate, i.e., mortality at the last follow-up speciﬁed, was 9.3% (21/
225) in patients treated with TNP/VAC, while this was 21.2% (41/
203) in standard treatment patients (OR 0.44, 95% CI 0.25–0.77). A
reduced short termmortality rate, i.e. in-hospital to 6months, was
observed in TNP/VAC-treated subjects: 8/172 (4.7%) as compared
to 21/149 (14.1%) in the conventionally treated subjects (OR 0.32,
95% CI 0.14–0.71). Middle-termmortality rates, i.e., mortality at 6–
12 months, were similar for the two treatment strategies: 15/70
(21.4%) in the TNP/VAC group and 24/72 (33.3%) in the standard
treatment group (OR 0.56, 95% CI 0.27–1.17).
4.9. Question 2 – cSSSI
‘‘Which are the most effective therapies in the treatment of
complicated skin and skin-structure infections, including surgical
site infections?’’
A total of 25 unique studies were identiﬁed (see Figure 2).6–
10,31–53 All of the studies retrieved were RCTs (see Tables 5 and 6).
Four studies were excluded for different reasons (one study drug
Table 5
Overall data: general characteristics of the selected studies—I
Study ID Aim Study design
Author Year of pub Journal
Noel9 2008 AAC Compare the safety and efﬁcacy of ceftobiprole to those of vancomycin+ ceftazidime, in patients with cSSSI Non-inferiority Double-blind
Noel31 2008 CID Compare the safety and efﬁcacy of ceftobiprole to those of vancomycin, for the treatment of skin infections due to Gram-
positive bacteria in which methicillin resistance is a concern
Non-inferiority Double-blind
Arbeit10 2004 CID Compare the safety and efﬁcacy of daptomycin with that of conventional therapy (penicillinase-resistant penicillin (PRP)
and vancomycin) for the treatment of patients with cSSSI requiring hospitalization
Non-inferiority Evaluator blinded
Cepeda32 2004 JAC Compare linezolid with teicoplanin in the treatment of Gram-positive infections in critically-ill patients Superiority Double-blind
Kohno33 2007 JAC Evaluate the efﬁcacy and safety of linezolid for the treatment of Japanese patients with nosocomial MRSA infections.
Vancomycin was chosen as the comparator
Descriptive Open-label
Lin34 2008 IJAA Compare the clinical efﬁcacy, safety, and tolerability of linezolid with those of vancomycin for the treatment of patients
with known or suspected Gram-positive infections and a clinical diagnosis of pneumonia or cSSTI
Descriptive Double-blind
Lipsky35 2004 CID Compare the efﬁcacy and safety of intravenous and oral formulations of linezolid with that of aminopenicillin/b-lactamase
inhibitors (plus vancomycin, if needed for MRSA) for treatment of patients with various types of diabetic foot infection
Equivalence Open-label
Weigelt6 2005 AAC Compare clinical efﬁcacy, safety, and tolerability of linezolid and vancomycin in the treatment of patientswith suspected or
proven methicillin-resistant, Gram-positive cSSTIs requiring hospitalization
Superiority Open-label
Itani36 2005 IJAA Sub-study of Weigelt 2005
Sharpe37 2005 AJS Not clearly speciﬁed. The study reports a comparison the efﬁcacy of linezolid with that of vancomycin Descriptive Open-label
Stevens7 2002 CID Compare the safety and efﬁcacy of linezolid with that of vancomycin in treating patients with presumed MRSA infections Equivalence Open-label
Li38 2001 Pharmacother Sub-study of Stevens 2002
Wilcox39 2004 JAC Compare linezolid and teicoplanin in the treatment of suspected or proven Gram-positive infections Equivalence Open-label
Nichols40 1999 JAC Compare efﬁcacy, tolerance, and safety of quinupristin–dalfopristin and standard therapy in patients with cSSSI caused by
Gram-positive bacteria
Equivalence Open-label
Breedt41 2005 AAC Determine the efﬁcacy and safety of tigecyclinemonotherapy and the combination of vancomycin and aztreonam (V/A) and
compare the non-inferiority of tigecycline to V/A in hospitalized patients with skin and skin-structure infections
Non-inferiority Double-blind
Ellis-Grosse42 2005 CID Determine the efﬁcacy and safety of tigecycline monotherapy and the combination of vancomycin and aztreonam in
hospitalized patients with skin and skin-structure infections
Non-inferiority Double-blind
Florescu43 2008 JAC Evaluate the safety and the clinical efﬁcacy of tigecycline in patients with selected serious infections caused by VRE and
MRSA. An active control arm was used to interpret the results
Favorable response Double-blind
Sacchidanand44 2005 IJID Compare safety and efﬁcacy of tigecycline vs. vancomycin+aztreonam in patients with cSSSI Non-inferiority Double-blind
AAC, Antimicrob Agents Chemother; CID, Clin Infect Dis; JAC, J Antimicrob Chemother; IJAA, Int J Antimicrob Agents; AJS, American Journal of Surgery; Pharmacother, Pharmacotherapy; IJID, Int J Infect Dis; cSSSI, complicated skin
and skin-structure infection; cSSTI, complicated skin and soft tissue infection; MRSA, methicillin-resistant Staphylococcus aureus; VRE, vancomycin-resistant enterococci.
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Table 6
Overall data: general characteristics of the selected studies—II
Study ID Enrolled
patients
Study drug Comparator Additional antibiotics
allowed
Duration of
therapy
(days)
Study design
Noel 20089 784 Ceftobiprole Vancomycin Aztreonam, metronidazole 7–14 Non-inferiority Double-blind
Noel 200831 828 Ceftobiprole Vancomycin+
ceftazidime
Metronidazole 7–14 Non-inferiority Double-blind
Arbeit 200410 1092 Daptomycin Vancomycin/PRP Aztreonam, metronidazole 7–14 Non-inferiority Evaluator blinded
Cepeda 200432 204a Linezolid Teicoplanin Various antibiotics allowed 3–28 Superiority Double-blind
Kohno 200733 154a Linezolid Vancomycin Aztreonam, gentamicin or
other anti-Gram-negative
7–21 Descriptive Open-label
Lin 200834 140a Linezolid Vancomycin Aztreonam 7–21 Descriptive Double-blind
Lipsky 200435 371 Linezolid Ampicillin–sulbactam
or amoxicillin–
clavulanic acid
Vancomycin, aztreonam 7–28 Equivalence Open-label
Weigelt 20056 1200 Linezolid Vancomycin Aztreonam or
other anti-Gram-negative
7–14 Superiority Open-label
Itani 200536 (Sub-study)
Sharpe 200537 117 Linezolid Vancomycin Any antibiotic not effective
against MRSA for two RCTs
7–21 Descriptive Open-label
Stevens 20027 460a Linezolid Vancomycin Aztreonam, gentamicin 7–14 Equivalence Open-label
Li 200138 (Sub-study)
Wilcox 200439 438a Linezolid Teicoplanin Aztreonam, gentamicin,
amikacin, ciproﬂoxacin,
ceftazidime, imipenem,
metronidazole
7–28 Equivalence Open-label
Nichols 199940 893 Quinupristin–
dalfopristin
Vancomycin/
cefazolin/oxacillin
Aztreonam 3–14 Equivalence Open-label
Breedt 200541 546 Tigecycline Vancomycin+aztreonam No Up to 14 Non-inferiority Double-blind
Ellis-Grosse 200542 1129 Tigecycline Vancomycin+aztreonam No Up to 14 Non-inferiority Double-blind
Florescu 200843 172 Tigecycline Vancomycin/ linezolid Anti-Gram-negative
antibiotics
7–28 Favorable response Double-blind
Sacchidanand 200544 573 Tigecycline Vancomycin+aztreonam No Up to 14 Non-inferiority Double-blind
PRP, penicillinase-resistant penicillin; MRSA, methicillin-resistant Staphylococcus aureus.
a The study enrolled also patients with other types of infection.
A. Pan et al. / International Journal of Infectious Diseases 14S4 (2010) S39–S53S48was not effective against MRSA for two,52,53 no data were reported
regarding the diagnostic criteria of cSSSI for two others50,51) and
six studies were excluded after panel discussion, since they
focused on drugs not yet registered, i.e., ceftaroline,45 dalbavan-
cin,46,47 and telavancin.48–50 Of the 18 studies from which data
were extracted, two reported pharmaco-economical data of two
studies included in the analysis.36,38 All the selected studies were
published from 1999 onwards.Table 7
Patients enrolled in the study and treated as per intention to treat (ITT), clinically and
Author Drugs ITT
Study drug Co
Study drug Study drug Cure Total Cu
Noel 20089 Ceftobiprole Vancomycin 309 397 30
Noel 200831 Ceftobiprole Vancomycin +
ceftazidime
448 547 22
Arbeit 200410 Daptomycin Vancomycin/ PRP 382 534 39
Kohno 200733 Linezolid Vancomycin NR NR N
Lin 200834 Linezolid Vancomycin 31 33 19
Lipsky 200435 Linezolid PRP (+ vancomycin) 165 241 77
Weigelt 20056 Linezolid Vancomycin 439 592 40
Sharpe 200537 l Linezolid Vancomycin NR NR N
Stevens 20027 Linezolid Vancomycin 64 122 54
Wilcox 200439 Linezolid Teicoplanin 113 123 10
Cepeda 200432 Linezolid Teicoplanin 23 32 10
Nichols 199940 Quinupristin–
dalfopristin
Vancomycin/
cefazolin/ oxacillin
197 450 19
Breedt 200541 Tigecycline Vancomycin +aztreonam 220 274 22
Ellis-Grosse
200542
Tigecycline Vancomycin +aztreonam 365 556 36
Florescu 200843 Tigecycline Vancomycin/ linezolid 55 81 20
Sacchidanand
200544
Tigecycline Vancomycin +aztreonam 165 292 16
NR, not reported.4.10. Patient populations
All studies evaluated both male and female adults; one study
also enrolled patients of 13 years of age,39 and a second one
enrolled patients 16 years of age.32 The mean age of the enrolled
populations ranged from 41.6 to 76 years. In all of the studies the
majority of patients were male, with the proportion ranging from
54% to 71%.35,39microbiologically evaluable at test of cure (TOC)
Clinically evaluable Microbiologically evaluable
mparator Study drug Comparator Study drug Comparator
re Total Cure Total Cure Total Cure Total Cure Total
0 387 263 282 259 277 NR NR NR NR
7 281 292 318 149 165 NR NR NR NR
7 558 372 446 384 456 21 28 25 36
R NR NR NR NR NR 13 18 4 10
29 30 33 19 24 NR NR NR NR
120 NR NR NR NR NR NR NR NR
2 588 436 462 394 436 NR NR NR NR
R NR 29 30 13 30 29 30 23 30
108 64 99 54 87 27 30 22 30
3 117 99 106 89 102 23 32 10 18
18 23 32 10 15 7 9 3 6
3 443 197 289 193 273 5 6 3 6
5 269 200 223 201 213 25 32 25 33
4 550 365 422 364 411 NR NR NR NR
23 NR NR NR NR NR NR NR NR
3 281 165 199 163 198 16 21 17 21
Table 9
Quality assessment of trials comparing the efﬁcacy of different antibiotics in the treatment of complicated skin and skin-structure infections, following the GRADE
recommendations
Study ID Design Quality Inconsistency Directness Attrition Bias Association (RR) Dose/response Confounders Total
Noel 20089 4 0 0 0 –1 0 0 0 0 3
Noel 200831 4 1 0 0 0 0 0 0 0 3
Arbeit 200410 4 2 0 0 0 0 0 0 0 2
Lin 200834 4 2 0 0 0 0 0 0 0 2
Lipsky 200435 4 2 0 0 0 1 0 0 0 1
Weigelt 20056 4 2 0 0 0 0 0 0 0 2
Kohno 200733 4 2 0 0 1 0 0 0 0 1
Sharpe 200537 4 2 0 0 1 1 0 0 0 2
Stevens 20027 4 2 0 0 1 0 0 0 0 1
Li 200138 4 2 0 0 1 0 0 0 0 1
Wilcox 200439 4 1 0 0 0 0 0 0 0 3
Cepeda 200432 4 0 0 0 0 0 0 0 0 4
Nichols 199940 4 1 0 0 1 1 0 0 0 1
Breedt 200541 4 2 0 0 0 0 0 0 0 2
Ellis-Grosse 200542 4 1 0 0 0 0 0 0 0 3
Florescu 200843 4 0 0 0 0 0 0 0 0 4
Sacchidanand 200544 4 0 0 0 0 0 0 0 0 4
Table 8
Overall data: study design and quality score, calculated using the Jadad modiﬁed method
Study ID Study design Random Validity of
randomization
Double-blind Validity of
double-blind
Withdrawal
and/or dropouts
Total Quality
Noel 20089 Double-blind 1 1 1 0 1 4 High
Noel 200831 Double-blind 1 0 1 0 0 2 Low
Arbeit 200410 Evaluator blinded 1 0 0 0 1 2 Low
Lin 200834 Double-blind 1 0 0 0 1 2 Low
Lipsky 200354 Open-label 1 0 NA NA 0 1 Low
Itani 200536 Open-label 1 0 NA NA 1 2 Low
Weigelt 20056 (Sub-study)
Kohno 200733 Open-label 1 0 NA NA 1 2 Low
Sharpe 200537 Open-label 1 0 NA NA 0 1 Low
Stevens 20027 Open-label 1 0 NA NA 1 2 Low
Li 200138 (Sub-study)
Wilcox 200439 Open-label 1 1 NA NA 1 3 High
Cepeda 200432 Double-blind 1 1 1 1 1 5 High
Nichols 199940 Open-label 1 1 NA NA 0 2 Low
Breedt 200541 Double-blind 1 0 0 0 1 2 Low
Ellis-Grosse 200542 Double-blind 1 0 0 1 1 3 High
Florescu 200843 Double-blind 1 1 1 1 1 5 High
Sacchidanand 200544 Double-blind 1 1 1 0 1 4 High
NA, not applicable.
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The interventions evaluated in the studies identiﬁed are
represented by an antibiotic monotherapy compared with another
monotherapy or with a combination of two antibiotics (see Table
6). The antibiotics studied were represented by: ceftobiprole,9,32
daptomycin,10 linezolid,6,7,32–49 quinupristin/dalfopristin,40 and
tigecycline.41–44 The comparators are reported in Table 6.
4.12. Outcomes
The primary outcome of clinical cure of cSSSI was reported in
14/16 studies on the overall population (see Table 7). Data
regarding clinical cure inMSSA infections could be retrieved in ﬁve
studies, data onMRSA in eight studies, while data on streptococcal
infectionswere reported in eight papers. No study reported clinical
data regarding enterococcal infections.
A microbiological analysis was reported in 9/16 studies. Data
regarding microbiological success for the different germs were
reported as follows:MSSA: eight studies;MRSA: nine; enterococci:
six; streptococci: eight.
AEs were reported in all but one study,37 while another study
reported only partial data.33 Data regarding mortality were
available in 12 studies, while they were not retrievable for
patients with cSSSI in four studies.7,34,39,43Pharmaco-economic data were also retrieved: the duration of
hospital stay was reported in three papers, and the length of
intravenous therapy and the total duration of therapy were
reported in 12 and ﬁve studies, respectively.
4.13. Risk of bias in included studies
Forty percent of the RCTs analyzed had a low risk of bias (6/15),
while the remaining studies had a high risk of bias, based upon the
modiﬁed Jadad score as reported in Table 8.19 This scoring system is
based upon an evaluation of ﬁve parameters: randomization,
double-blinding, dropouts and withdrawals, generation of random
numbers, and allocation concealment. For each of these parameters,
if theywere speciﬁed following the Jadad criteria, a pointwas given.
The attrition, i.e., the number of the initially randomized
patients that were not clinically evaluable, was similar among the
two study arms in all studies, in most papers below 25%, varying
from about 10%31,35 to over 45%.37
4.14. Global overview
A total of 8278 patients were enrolled in the 16 studies
analyzed; of these, 8158 (98.6%)were randomized to receive either
the intervention drug (patient group, n = 4335) or the compara-
tor(s) (n = 3823). An infection due toMRSAwas diagnosed in 1698/
A. Pan et al. / International Journal of Infectious Diseases 14S4 (2010) S39–S53S508278 (20.5%) of the enrolled patients. The other Gram-positive
organisms commonly reported were: MSSA (2309 patients, 27.9%),
streptococci (918 patients, 11.1%), and enterococci (236 patients,
2.9%).
4.15. Effects of intervention – primary outcomes
Themethodological quality of the studieswas analyzed through
the GRADE system (see Table 9). Data regarding treatment success
for intention to treat (ITT) at TOC visit were available for 13 of the
16 studies, while data regarding clinical efﬁcacy at TOC visit were
retrievable from 10 papers (see Table 7). In most RCTs the
comparison was performed between the intervention drug and
vancomycin or, less frequently, teicoplanin. In one case, the study
compared linezolid with a combination of penicillin and a b-
lactamase inhibitor (PBLI).35
The overall efﬁcacy was similar for study drugs and compara-
tors in most studies. A signiﬁcant difference was observed in three
studies, all of them comparing linezolid with vancomycin.6,35,38 A
trend towards a signiﬁcant difference was observed in a further
study comparing linezolid with PBLI/vancomycin.35
When the subset of patients with a microbiological diagnosis of
MRSA infection was analyzed, some studies reported data on
clinical efﬁcacy only,6,9,31,35 some on microbiology efﬁcacy
only,10,32,33,40,42,44 and three on both.7,33,41 Two studies only
observed a signiﬁcant difference, either clinical6 or microbiolog-
ical:37 in both cases linezolid was superior to vancomycin. Of note,
the absolute number of MRSA patients evaluated in tigecycline
studies41,43 was very small, i.e., 93.
Data regarding mortality were reported in 12 studies. The
studies that included only patients with cSSSI reported very low
mortality rates, varying between 0% and 1.5%. No difference was
observed throughout the comparisons.
The incidence of AEs, was reported in 14/16 studies. Notably,
only one study,9 reported the World Health Organization (WHO)
grading system of AE, with serious AE havingWHO grade>3. Three
study drugs showed a higher incidence of AE than the comparator:
linezolid, quinupristin/dalfopristin, and tigecycline. The studies
comparing linezolid with a glycopeptide/PBLI showed a signiﬁ-
cantly lower proportion of AE in the control group (36.8% vs. 42.6%
for glycopeptide/PBLI and linezolid, respectively). This difference
persisted even if the patients included in the study by Lipsky
et al.,35 based upon PBLI, were not considered (OR 1.23, 95% CI
1.03–1.48). In these studies the most common AEs in the linezolid
group were represented by diarrhea, nausea, anemia, thrombocy-
topenia, and liver disease, while the glycopeptide-treated group
presented more frequently renal failure and rash. Quinupristin/
dalfopristin was associated with a signiﬁcantly higher proportion
of AEs than vancomycin/penicillinase-resistant penicillin (PRP):
62.9% vs. 54%, mainly gastrointestinal problems and venous
events. Finally, tigecycline was associated with a higher incidence
of AE than vancomycin plus aztreonam: 67.8% vs. 61.3%, the most
common AE for tigecycline being gastrointestinal symptoms, such
as nausea (over a third of the patients) and vomiting, while
patients on vancomycin/aztreonam complained more frequently
of skin problems and abnormal liver function tests.
Serious AEs (SAEs) were reported in detail in 14 studies, while
one study47 reported only the total number of SAEs in the whole
study population. No difference was observed between any study
arm.
4.16. Secondary outcomes
Microbiological cure was reported in nine of the 16 studies (see
Table 7). No signiﬁcant difference was reported between the
intervention drug and the comparator in all but one comparison(linezolid) that determined a signiﬁcantly better microbiological
eradication than the comparators (OR 2.17, 95% CI 1.38–3.42).
The duration of intravenous therapy was reported by 12
studies.9,10,31,34,35,37–40,42,44,45 In seven of these studies, one
comparing daptomycin with vancomycin/PRP,10 ﬁve linezolid vs.
glycopeptide/PRP,35–39 and one quinupristin/dalfopristin,40 the
intervention arm showed a shorter duration of intravenous
therapy.
The duration of hospital stay was analyzed in three studies, all
of them comparing linezolid with vancomycin. In two of these
three studies, a shorter duration of hospital stay was observed.
Notably, two studies, one by Itani and colleagues36 and the other
by Li and colleagues,38 speciﬁcally addressed pharmaco-economic
issues, and one single study37 compared the cost of linezolid
treatment with that of standard therapy, i.e., vancomycin. The
authors calculated a signiﬁcant saving of money when the patients
were treated with linezolid.
5. From the evidence to the recommendations
5.1. Question 1
‘‘What is the efﬁcacy of topical negative pressure wound
treatment as compared to the standard of care, in the treatment of
severe surgical site infections, i.e., deep, under the fascial and
muscle layers, due to Gram-positive microorganisms?’’
5.2. Discussion
The application of negative pressure to favor wound healing
was introduced into clinical practice in the 1960 s, but was
standardized with the introduction of TNP/VAC in the 1990s.54 The
possibility of maintaining a closed and clean environment, and the
continuous drainage of necrotic and bacterial debris, could
theoretically improve the time taken to wound cure.54 Due to
the limitation of alternative effective therapies, and to the
experience of some centers, TNP/VAC has become, in many
hospitals, the standard of care for difﬁcult to treat chronic wounds,
including post-sternotomy mediastinitis, despite the fact that its
efﬁcacy and complications in this setting have not been fully
investigated.17
We analyzed 699 papers, and did not ﬁnd a single RCT that
addressed the problem. A multicenter European trial on TNP/VAC
treatment of post-sternotomy mediastinitis has recently been
prematurely terminated due to a lack of patient enrolment.55 We
identiﬁed 10 comparative studies that satisﬁed all inclusion
criteria, with an overall medium risk of bias, that enrolled a total of
562 patients (see Tables 1 and 2).21–30 It was not possible to
identify, within the selected studies, the clinical outcome of
infections stratiﬁed by Gram-positive or Gram-negative patho-
gens. The overall analysis performed showed that TNP/VAC was
signiﬁcantly more effective in 6/10 studies than standard therapy
in the cure of post-sternotomy mediastinitis and of deep sternal
wound infections, which, to date, represent the major indications
of this therapeutic approach in the setting of an infection. Time to
wound healing was reported in two of the 10 studies23,26 and no
signiﬁcant difference was observed between the two treatments.
No increased risk of complication was observed among TNP/VAC-
treated patients, although one patient died of ventricular rupture
due to TNP/VAC.
Both short-term (in-hospital to 3 months) and last follow-up
visit mortality rates were signiﬁcantly lower in TNP/VAC-treated
patients than in the standard care patients, while middle-term
mortality (6–12 months) was similar in the two groups.
Patients treated with TNP/VAC had a shorter duration of
hospital stay. No study compared the cost of TNP/VAC and
A. Pan et al. / International Journal of Infectious Diseases 14S4 (2010) S39–S53 S51standard therapy, nor did any study address the quality of life
issues.
There are several limitations to the interpretation of these
results. First of all, the overall quality of the studies is generally
low, with no available well-designed RCTs. The studies analyzed
generally show a medium risk of bias. Only in three cases did a
study have a GRADE score 1 (see Table 4).23,25,27 In ﬁve cases the
GRADE score was zero,22,24,28–30 while in the remaining two
studies it was1.21,29 However, when only the three higher quality
studies were analyzed, the overall results were conﬁrmed: a
signiﬁcant difference in the effect of TNP/VAC vs. standard therapy
was still observed (OR 9.19, 95% CI 2.77–30.48). These three studies
did not show any signiﬁcant difference in mortality between the
two treatment strategies (OR 0.56, 95% CI 0.27–1.17).
Second, the TNP/VAC was not well standardized among the
studies: it was used at different pressures and the foam was
changed at different time intervals. Third, the debridement and
drainage procedures used as comparator varied signiﬁcantly
between and among centers. Fourth, in patients with post-
sternotomy mediastinitis and deep surgical site infection, antibi-
otic treatment is mandatory and should preferably be prescribed
by an infectious disease consultant. Unfortunately, no speciﬁc
information was reported in any study regarding the antibiotic
treatment, i.e., molecule, dose, duration. Finally this limited
amount of comparative data is restricted almost exclusively to
one single type of infection: post-sternotomy infections.Recommendations
The use of TNP/VAC in patients with a post-sternotomy
infection, eithermediastinitis or deep surgical site infection, is a
possible alternative to the standard therapy (grade D). The cost-
effectiveness of TNP/VAC should be carefully evaluated.
In the treatment of infected wounds TNP/VAC should be
reserved only for patients with post-sternotomy infections,
including mediastinitis (grade D).
A standardized protocol, both for the use of TNP/VAC and for
the standard care of the infected wound should be deﬁned in5.3. Question 2
‘‘Which are the most effective therapies in the treatment of
complicated skin and skin-structure infections, including surgical
site infections?’’
5.4. Discussion
Complicated skin and skin-structure infections are caused by
Gram-positive cocci in the majority of cases.1 Treatment of cSSSI
has been, over the years, an area of intense investigation that has
permitted the registration of most of the novel antibiotics,
particularly of those active against MRSA, such as linezolid,
tigecycline, and daptomycin. With the new epidemiological
situation, characterized by a dramatic increase in the proportion
of CA-MRSA in North America1 and by the emergence of LA-MRSA
in Europe,3 with both germs frequently causing cSSSI, there is a
need to better deﬁne the potency and tolerability of the different
drugs indicated in the treatment of these infections.
The analysis of the literature identiﬁed seven different
registered anti-MRSA drugs for which RCTs have been published
since 1990. In most cases the performed studies evaluated the
efﬁcacy of a novel drug as compared to the standard of care,
represented in most cases by a glycopeptide, generally vancomy-
each cardiac and thoracic surgery department to reduce intra-
hospital variability (grade D).cin and, less frequently, teicoplanin, or in a single study, by PBLI
(see Table 6). Notably, as in other areas of pharmacological
research, most studies aimed to demonstrate a non-inferiority of
the newer drug as compared to the older: in the 18 studies that we
analyzed, therewere only two superiority studies. Due to the high
costs of clinical research, we think that systematic reviews and
meta-analyses will represent an important tool in the future to
better deﬁne which are the most potent and better tolerated
drugs.
We applied a methodology adapted from the GRADE Working
Group to assign a strength level to the recommendations. The
GRADE score of the studies analyzed was high (GRADE 4) in three
of 18 studies (17%).32,43,44 Four studies (22%) were of medium
quality (GRADE 3)9,31,39,42 and the majority, i.e., the remaining 11
studies (61%) were of low quality (GRADE 2).
Comparisons between these different drugs allowed the
veriﬁcation that ceftobiprole, daptomycin, quinupristin/dalfopris-
tin, and tigecycline are as effective as vancomycinwhen evaluating
the clinical efﬁcacy for ITT analysis. The only comparison that
permitted the identiﬁcation of a signiﬁcant difference between the
study drugs was linezolid vs. glycopeptide/PBLI, where linezolid
performed better than the comparator in three out of seven
studies. When the analysis was performed on the population of
patients with conﬁrmed MRSA infections, the superiority of
linezolid vs. glycopeptide/PRP was observed in two of six studies.
No other difference was observed for any other drug. No difference
in mortality was observed in any comparison, as was expected due
to the low overall mortality of cSSSI.
The analysis on AEs yielded interesting results. The incidence of
SAEs was similar throughout all comparisons. The global incidence
of AEs was similar between the new cephalosporin and vancomy-
cin/PRP, as well as between daptomycin and vancomycin/PRP. All
the other newer drugs, i.e., linezolid, quinupristin/dalfopristin, and
tigecycline, were tolerated signiﬁcantly worse than the glycopep-
tides. It is interesting to point out that vancomycin is generally
considered a relatively toxic and not well tolerated drug.
Data regarding duration of hospital stay were available only for
three studies, all evaluating linezolid, and showing a reduced
duration of hospital stay in patients treated with this drug.
Furthermore, the majority of studies reported the duration of
intravenous therapy, showing a signiﬁcantly shorter duration of
intravenous therapy consistently reported in patients treated with
linezolid as compared with vancomycin/PRP. A shorter duration of
intravenous therapy was also reported in two studies comparing
daptomycin and quinupristin/dalfopristin with vancomycin/PRP.
One single study evaluated the costs associated with linezolid vs.
vancomycin in MRSA-infected patients, with a signiﬁcant advan-
tage for linezolid. Data regarding the pharmaco-economic issue are
in favor of linezolid, to-date the only oral drug with anti-MRSA
activity among the newer antibiotics. Since the newer drugs have
costs that are consistently higher than vancomycin, the economic
analysis plays an important role in the choice of the antibiotic to be
used. No pharmaco-economic analysis was found speciﬁcally
addressing cSSSI, performed within an RCT.
Among the limitations to this analysis, the most important is
that most of the RCTs evaluating linezolid were open-label, thus of
reduced quality as compared with the double-blind study design.
The quality score applying the modiﬁed Jadad methodology19 of
the studies evaluating linezolid was generally low to medium (see
Table 9). Similarly, a low GRADE score was observed in most
studies. One single small study, evaluating 60 patients, reported a
cost-effectiveness analysis.37 No study was found that made a
comparison with the efﬁcacy of older drugs with at least a partial
anti-MRSA activity, such as tetracycline, clindamycin, co-trimox-
azole, and fusidic acid. RCTs have been performed with some of
these drugs in uncomplicated skin and soft tissue infections,
A. Pan et al. / International Journal of Infectious Diseases 14S4 (2010) S39–S53S52although, in our opinion, further investigation is needed, due also
to the availability of oral formulations for some of these drugs.
Interestingly, in most studies analyzed, therapeutic drug
monitoring of vancomycin was not a part of the study protocol,
being left to the decision of the investigator. This lack of
vancomycin therapeutic dose monitoring could have led to both
increased toxicity due to high trough levels, as well as reduced
efﬁcacy due to low concentrations.
Finally, the studies analyzed did not enroll patients with severe
disease, such as necrotizing fasciitis, gangrene, and ecthyma
gangrenosum, thus limiting the utility of the results, although
some papers did include patients with positive blood stream
infections.Recommendations
Glycopeptides (vancomycin and teicoplanin) should be
considered as the standard of care in patients with cSSSI due
to MRSA (grade A).
Linezolid appears to be more effective than glycopeptides
(grade C). Linezolid could be an alternative treatment to
glycopeptides despite the low to medium methodological
quality of analyzed trials (grade D).
Newer drugs, tigecycline (grade B) and daptomycin (grade
C), are as effective as glycopeptides.
When choosing the therapeutic strategy, the pharmaco-
economic issue should be considered, i.e., cost of the drug,
duration of intravenous therapy, length of hospital stay, and
early discharge; a switch to the oral drug should be made
whenever possible (grade C).
Always carefully consider the pharmacokinetic and phar-
macodynamic parameters of chosen drugs. Monitor glycopep-Acknowledgement
The GISIG Consensus Conference was organized with support
from an unrestricted educational grant from Pﬁzer.
We are thankful to Dr Mark Wilson who provided us with data
on cSSSI retrieved from his study.
We wish to thank Tom Jefferson for sharing his expertise and
ideas with us.
Conﬂict of interest
All members of the faculty of GISIG – G. Carosi, R. Cauda, E.
Concia, S. Esposito, G. Ippolito, F.N. Lauria, M. Moroni, E. Nicastri, A.
Pan, G. Sganga, S. Stefani – report no other potential conﬂict of
interest except as reported in the speciﬁc section.
The members of the working group have no speciﬁc conﬂict of
interest to report.
Funding
For the present research, all members of the faculty of GISIG
received a fee from the organizing secretariat of the GISIG Project.
The members of the working group have no funding to report.
Additional Conﬂict of interest
Conﬂict of interest for R. Cauda: GlaxoSmithKline, Gilead,
Bristol Myers Squibb, Boehringer Ingelheim, Pﬁzer, Abbott, Merck
Sharp & Dohme, Wyeth. Funding received from GlaxoSmithKline,
tide trough levels and adapt their dosage according to the
available guidelines (grade D).Gilead, Bristol Myers Squibb, Boehringer Ingelheim, Pﬁzer, Abbott,
Merck Sharp & Dohme. S. Esposito has received fees for speaking at
national and internationalmeetings and for consulting onAdvisory
boards from Pﬁzer, Novartis farma and Wyeth Lederle. G. Sganga
has received honoraria for speaking for Pﬁzer. G. Ippolito and F.N.
Lauria have received expert opinion fees from Pﬁzer. E. Nicastri has
received paid expert opinion from MSD and Pﬁzer. A. Pan has
received paid expert opinion fees from Janssen.
References
1. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, et al.
Practice guidelines for the diagnosis and management of skin and soft-tissue
infections. Clin Infect Dis 2005;41:1373–406.
2. Stryjewski ME, Chambers HF. Skin and soft-tissue infections caused by com-
munity-acquired methicillin-resistant Staphylococcus aureus. Clin Infect Dis
2008;46(Suppl 5):S368–77.
3. Wulf M, Voss A. MRSA in livestock animals—an epidemic waiting to happen?
Clin Microbiol Infect 2008;14:519–21.
4. Pan A, Battisti A, Zoncada A, Bernieri F, Boldini M, Franco A, et al. Community-
acquired methicillin-resistant Staphylococcus aureus ST398 infection. Italy
Emerg Infect Dis 2009;15:845–7.
5. Smith J. Debridement of diabetic foot ulcers. Cochrane Database Syst Rev
2002;(4):CD003556.
6. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus
vancomycin in treatment of complicated skin and soft tissue infections. Anti-
microb Agents Chemother 2005;49:2260–6.
7. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus
vancomycin for the treatment of methicillin-resistant Staphylococcus aureus
infections. Clin Infect Dis 2002;34:1481–90.
8. Stryjewski ME, Graham DR, Wilson SE, O’Riordan W, Young D, Lentnek A, et al.
Telavancin versus vancomycin for the treatment of complicated skin and skin-
structure infections caused by Gram-positive organisms. Clin Infect Dis
2008;46:1683–93.
9. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a
double-blind, randomized trial of ceftobiprole treatment of complicated skin
and skin structure infections caused by Gram-positive bacteria. Antimicrob
Agents Chemother 2008;52:37–44.
10. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efﬁcacy
of daptomycin for the treatment of complicated skin and skin-structure infec-
tions. Clin Infect Dis 2004;38:1673–81.
11. Singer AJ, Dagum AB. Current management of acute cutaneous wounds. N Engl J
Med 2008;359:1037–46.
12. Diehr S, Hamp A, Jamieson B, Mendoza M. Clinical inquiries. Do topical anti-
biotics improve wound healing? J Fam Pract 2007;56:140–4.
13. Bradley M, Cullum N, Nelson EA, Petticrew M, Sheldon T, Torgerson D. System-
atic reviews of wound caremanagement: (2). Dressings and topical agents used
in the healing of chronic wounds. Health Technol Assess 1999;3:1–35.
14. Dryburgh N, Smith F, Donaldson J, Mitchell M. Debridement for surgical
wounds. Cochrane Database Syst Rev 2008;(3):CD006214.
15. FleischmannW, Strecker W, Bombelli M, Kinzl L. [Vacuum sealing as treatment
of soft tissue damage in open fractures]. Unfallchirurg 1993;96:488–92.
16. Argenta LC, Morykwas MJ. Vacuum-assisted closure: a new method for wound
control and treatment: clinical experience. Ann Plast Surg 1997;38:563–76.
17. Raja SG, Berg GA. Should vacuum-assisted closure therapy be routinely used for
management of deep sternal wound infection after cardiac surgery? Interact
Cardiovasc Thorac Surg 2007;6:523–7.
18. van Rijen M, Bonten M, Wenzel R, Kluytmans J. Mupirocin ointment for
preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database
Syst Rev 2008;(4):CD006216.
19. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for preven-
tion of surgical site infection, 1999. Hospital Infection Control Practices Advi-
sory Committee. Infect Control Hosp Epidemiol 1999;20:250–78.
20. Lauria FN, De Carli G, Nicastri E. Resistant and multi-resistant Gram-positive
severe infections: the GISIG working methodology. Int J Infect Dis 2010;14S:
S13–7.
21. Berg HF, Brands WG, van Geldorp TR, Kluytmans-VandenBergh FQ, Kluytmans
JA. Comparison between closed drainage techniques for the treatment of
postoperative mediastinitis. Ann Thorac Surg 2000;70:924–9.
22. Fleck TM, Koller R, Giovanoli P, Moidl R, Czerny M, Fleck M, et al. Primary or
delayed closure for the treatment of poststernotomy wound infections? Ann
Plast Surg 2004;52:310–4.
23. Fuchs U, Zittermann A, Stuettgen B, Groening A, Minami K, Koerfer R. Clinical
outcome of patients with deep sternal wound infection managed by vacuum-
assisted closure compared to conventional therapy with open packing: a
retrospective analysis. Ann Thorac Surg 2005;79:526–31.
24. Scholl L, Chang E, Reitz B, Chang J. Sternal osteomyelitis: use of vacuum-assisted
closure device as an adjunct to deﬁnitive closure with sternectomy and muscle
ﬂap reconstruction. J Card Surg 2004;19:453–61.
25. Simek M, Hajek R, Zalesk B, Molitor M, Lonsky V, Grulichova J, et al. Topical
negative pressure versus conventional treatment of deep sternal wound infec-
tion in cardiac surgery. European Wound Management Association Journal
2008;8:17–20.
A. Pan et al. / International Journal of Infectious Diseases 14S4 (2010) S39–S53 S5326. Song DH, Wu LC, Lohman RF, Gottlieb LJ, Franczyk M. Vacuum assisted closure
for the treatment of sternal wounds: the bridge between debridement and
deﬁnitive closure. Plast Reconstr Surg 2003;111:92–7.
27. Catarino PA, Chamberlain MH, Wright NC, Black E, Campbell K, Robson D, et al.
High-pressure suction drainage via a polyurethane foam in the management of
poststernotomy mediastinitis. Ann Thorac Surg 2000;70:1891–5.
28. Segers P, De Jong AP, Kloek JJ, De Mol BA. Poststernotomy mediastinitis:
comparison of two treatment modalities. Interact Cardiovasc Thorac Surg
2005;4:555–60.
29. Sjo¨gren J, Nilsson J, Gustafsson R, Malmsjo M, Ingemansson R. The impact of
vacuum-assisted closure on long-term survival after post-sternotomy medias-
tinitis. Ann Thorac Surg 2005;80:1270–5.
30. Colwell AS, Donaldson MC, Belkin M, Orgill DP. Management of early groin
vascular bypass graft infections with sartorius and rectus femoris ﬂaps. Ann
Plast Surg 2004;52:49–53.
31. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial
comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the
treatment of patients with complicated skin and skin-structure infections. Clin
Infect Dis 2008;46:647–55.
32. Cepeda JA, Whitehouse T, Cooper B, Hails J, Jones K, Kwaku F, et al. Linezolid
versus teicoplanin in the treatment of Gram-positive infections in the critically
ill: a randomized, double-blind, multicentre study. J Antimicrob Chemother
2004;53:345–55.
33. Kohno S, Yamaguchi K, Aikawa N, Sumiyama Y, Odagiri S, Aoki N, et al. Linezolid
versus vancomycin for the treatment of infections caused by methicillin-
resistant Staphylococcus aureus in Japan. J Antimicrob Chemother 2007;
60:1361–9.
34. Lin DF, Zhang YZ, Wu JF, Wang F, Zheng JC, Miao JZ, et al. Linezolid for the
treatment of infections caused by Gram-positive pathogens in China. Int J
Antimicrob Agents 2008;32:241–9.
35. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a
randomized, multicenter, open-label trial of linezolid versus ampicillin–sul-
bactam/amoxicillin–clavulanate. Clin Infect Dis 2004;38:17–24.
36. Itani KM, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and
duration of intravenous treatment compared with vancomycin for complicated
skin and soft tissue infections due to suspected or proven methicillin-resistant
Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2005;26:442–8.
37. Sharpe JN, Shively EH, Polk HC. Clinical and economic outcomes of oral linezolid
versus intravenous vancomycin in the treatment of MRSA-complicated, lower-
extremity skin and soft-tissue infections caused by methicillin-resistant Staph-
ylococcus aureus. Am J Surg 2005;189:425–8.
38. Li Z, Willke RJ, Pinto LA, et al. Comparison of length of hospital stay for patients
with known or suspected methicilliresistant Staphylococcus species infections
treated with linezolid or vancomycin: a randomized, multi center trial. Phar-
macotherapy 2001;21:263–74.
39. Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the
treatment of suspected or proven Gram-positive infections. J Antimicrob Che-
mother 2004;53:335–44.
40. Nichols RL, Graham DR, Barriere SL, Rodgers A, Wilson SE, Zervos M, et al.
Treatment of hospitalized patients with complicated Gram-positive skin and
skin structure infections: two randomized, multicentre studies of quinupristin/
dalfopristin versus cefazolin, oxacillin or vancomycin. Synercid Skin and Skin
Structure Infection Group. J Antimicrob Chemother 1999;44:263–73.
41. Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, et al. Safety and
efﬁcacy of tigecycline in treatment of skin and skin structure infections: resultsof a double-blind phase 3 comparison study with vancomycin–aztreonam.
Antimicrob Agents Chemother 2005;49:4658–66.
42. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E. The efﬁcacy and safety of
tigecycline in the treatment of skin and skin-structure infections: results of 2
double-blind phase 3 comparison studies with vancomycin–aztreonam. Clin
Infect Dis 2005;41(Suppl 5):S341–53.
43. Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, et al.
Efﬁcacy and safety of tigecycline compared with vancomycin or linezolid for
treatment of serious infections withmethicillin-resistant Staphylococcus aureus
or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind,
randomized study. J Antimicrob Chemother 2008;62(Suppl 1):i17–28.
44. Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis Grosse E, et al.
Efﬁcacy and safety of tigecycline monotherapy compared with vancomycin
plus aztreonam in patients with complicated skin and skin structure infections:
results from a phase 3, randomized, double-blind trial. Int J Infect Dis
2005;9:251–61.
45. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard
therapy in treatment of complicated skin and skin structure infections. Anti-
microb Agents Chemother 2007;51:3612–6.
46. Jauregui LE, Babazadeh S, Seltzer E, Goldberg L, Krievins D, Frederick M, et al.
Randomized, double-blind comparison of once-weekly dalbavancin versus
twice-daily linezolid therapy for the treatment of complicated skin and skin
structure infections. Clin Infect Dis 2005;41:1407–15.
47. Seltzer E, Dorr MB, Goldstein BP, Perry M, Dowell JA, Henkel T. Once-weekly
dalbavancin versus standard-of-care antimicrobial regimens for treatment of
skin and soft-tissue infections. Clin Infect Dis 2003;37:1298–303.
48. Stryjewski ME, O’Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, et al.
Telavancin versus standard therapy for treatment of complicated skin and
soft-tissue infections due to Gram-positive bacteria. Clin Infect Dis 2005;
40:1601–7.
49. Stryjewski ME, Chu VH, O’RiordanWD,Warren BL, Dunbar LM, Young DM, et al.
Telavancin versus standard therapy for treatment of complicated skin and skin
structure infections caused by Gram-positive bacteria: FAST 2 study. Antimicrob
Agents Chemother 2006;50:862–7.
50. Van der Auwera P, Aoun M, Meunier F. Randomized study of vancomycin
versus teicoplanin for the treatment of Gram-positive bacterial infections
in immunocompromised hosts. Antimicrob Agents Chemother 1991;35:
451–7.
51. Wilcox MH, Tack KJ, Bouza E, Herr DL, Ruf BR, Ijzerman MM, et al. Complicated
skin and skin-structure infections and catheter-related bloodstream infections:
noninferiority of linezolid in a phase 3 study. Clin Infect Dis 2009;48:203–12.
52. Stevens DL, Smith LG, Bruss JB, McConnell-Martin MA, Duvall SE, Todd WM,
et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin–
dicloxacillin for treatment of complicated skin and soft tissue infections.
Antimicrob Agents Chemother 2000;44:3408–13.
53. Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous/
oral moxiﬂoxacin versus intravenous piperacillin–tazobactam followed by oral
amoxicillin–clavulanate for the treatment of complicated skin and skin struc-
ture infection. Int J Antimicrob Agents 2005;26:357–65.
54. Sjogren J, Malmsjo M, Gustafsson R, Ingemansson R. Poststernotomy medias-
tinitis: a review of conventional surgical treatments, vacuum-assisted closure
therapy and presentation of the Lund University Hospital mediastinitis algo-
rithm. Eur J Cardiothorac Surg 2006;30:898–905.
55. Gregor S, Maegele M, Sauerland S, Krhan JF, Peinemaa F, Lange S. Negative
pressure wound therapy: a vacuum of evidence? Arch Surg 2008;143:189–96.
